Background: Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II study evaluated docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5-FU (TEF), and docetaxel/oxaliplatin/capecitabine (TEX) in patients with advanced GC.
and on taxane-containing triplet combinations [10] [11] [12] [13] [14] [15] [16] . The combination of docetaxel, cisplatin, and infusional 5-FU (DCF) significantly improved PFS and OS compared with CF [10] . Follow-up studies reported improvements in clinical benefit [17] and quality of life [18] . However, the DCF regimen has been associated with increased toxicity compared with CF [10] and has not been used extensively in clinical practice or as the preferred chemotherapy backbone in clinical trials evaluating new targeted agents. More recent phase II studies reported good efficacy and tolerability with epirubicin/oxaliplatin/docetaxel [13] , biweekly docetaxel/oxaliplatin (TE) and infusional 5-FU (TEF) [19] , and docetaxel/oxaliplatin/capecitabine (TEX) [11] . A split-dose docetaxel, cisplatin, and leucovorin/fluorouracil regimen was also highly active with reduced toxicity compared with the DCF regimen [20] . The relative benefit : risk profiles of doublet versus triplet therapy in advanced GC remain unknown [21] .
This phase II study was conducted to evaluate the efficacy and tolerability of docetaxel plus oxaliplatin with or without infusional 5-FU or capecitabine in patients with advanced GC and to identify a regimen with a better therapeutic index than DCF. methods patients Eligible patients were ≥18 years old with Karnofsky performance status (KPS) >70 and histologically proven metastatic (measurable and/or evaluable) or locally recurrent gastric adenocarcinoma (including carcinoma of the gastro-oesophageal junction). Prior palliative chemotherapy was not permitted. Prior adjuvant (and/or neoadjuvant) 5-FU, cisplatin, and epirubicin were allowed if relapse occurred >12 months after the end of chemotherapy. A period of ≥4 weeks had to have elapsed since the last round of palliative radiotherapy and of ≥3 weeks since last surgery. The main exclusion criterion was the presence of neurosensory symptoms of the National Cancer Institute Common Terminology Criteria for Adverse events (NCI-CTAE) grade ≥2. The study was conducted in accordance with the Declaration of Helsinki (1964). All patients provided written informed consent.
study design and treatments
This was a prospective, multinational, randomized, phase II study comparing TE, TEF, and TEX. The study was conducted in two parts ( Figure 1 ). Part 1 determined the optimal doses for each investigational regimen. Docetaxel was escalated in the TEX arm in an attempt to mimic the dose original articles
Annals of Oncology intensity of docetaxel used in the TAX325 study [10] . In the TE arm, the aim was to use a higher dose of docetaxel (75 mg/m 2 ) than that used in a previous study of TE in GC (60 mg/m 2 [22] ), and it was therefore planned to escalate oxaliplatin starting at a lower dose of 100 mg/m 2 (versus 130 mg/m 2 previously [22] ). An Independent Data Monitoring Committee (IDMC) reviewed safety data collected from approximately 10 randomized patients at each of the two dose levels. The efficacy and safety of the optimal dose regimens selected in part 1 were evaluated in part 2. Patients were randomized centrally using an interactive voice response system, with stratification by country, weight loss (≤5% or >5%), and disease measurability (measurable or evaluable-only lesions). Treatment was administered until disease progression, unacceptable toxicity, or patient withdrawal of consent.
assessments
The primary efficacy parameter was PFS, defined as the time from date of randomization to date of first progression or death from any cause, whichever occurred first. OS was measured as the time from date of randomization to date of death from any cause. Tumour response was evaluated every 8 weeks and classified according to best overall response (World Health Organization criteria). The overall response rate (ORR) included partial and complete responses. Best overall response was the best response designation recorded from the start of treatment until disease progression. Responses were confirmed by two evaluations conducted ≥4 weeks apart. Safety was evaluated by adverse event (AE) reporting and grading (NCI-CTCAE Version 3.0), haematology and laboratory assessments, physical and neurological examinations, vital signs, weight, and performance status.
statistical analyses
In part 1, an estimated 60 patients were required to determine the optimal doses. In part 2, the study size was calculated with an assumed 23% progression-free rate at 12 months, based on results from the V325 study [10] . To obtain a precision of 10% of the 95% confidence interval (CI), an estimated 68 patients per treatment arm were required. The upper limit of the 95% CI was 32.6%, corresponding to a median time-to-progression of 7.4 months. Assuming a drop-out rate of 15%, the target recruitment was 240 patients (80 per arm). Patients treated at the optimal dose in part 1 were included in part 2.
The primary efficacy population was the full analysis population (FAP: all randomized and treated patients analysed in the arm to which they were randomized), with supportive analyses conducted using the intent-to-treat (ITT: all randomized patients) and per protocol (PP: assessable patients [received study treatment and had ≥1 post-baseline tumour assessment] without any major protocol violation) populations. Cancer located in one or more of the following organs/tissues: brain, oesophagus, stomach, duodenum, small intestine, colon, rectum, liver, pancreas, gallbladder/biliary tract, lung, heart, bladder, kidneys, adrenal glands, prostate, testis, ovary, uterus, eye, and thyroid. The primary end point was PFS. Secondary end points included OS, ORR, and safety. The analyses of efficacy and safety were primarily descriptive and no statistical comparisons between study arms were generated for the end points presented in this report. For PFS and OS, unadjusted KaplanMeier estimates were generated along with median values (and 95% CI). A post hoc multivariate analysis (Cox proportional hazards model) was conducted to determine whether the TEF regimen was a favourable prognostic factor for PFS and OS; further details of this analysis are provided in supplementary Tables S1 and S2, available at Annals of Oncology online. Descriptive statistics are presented for ORR with exact 95% CI determined using the Clopper-Pearson method. The safety data are presented descriptively for the safety population ( patients who received at least one dose of study drug at the optimal dose). Statistical calculations were carried out using SAS® version 9.2.
therapeutic index
A post hoc analysis was conducted to evaluate overall clinical benefit, which was estimated by calculating a therapeutic index incorporating efficacy (PFS) and a key safety parameter (febrile neutropenia). Median PFS was plotted against the incidence (%) of febrile neutropenia for each of the three regimens investigated in this study and compared with the equivalent data reported previously for DCF and CF [10] . Figure 1 . A total of 254 patients were randomly allocated to one of the three treatment arms or to receive the optimal treatment regimen in part 1 and continued with treatment (ITT population). Of these, 248 patients received treatment (full analysis and safety populations). The majority (69%) of patients were male; mean age was 59 years. Baseline disease characteristics were similar across the three treatment arms (Table 1 ). Overall, 52% of patients had ≤5% weight loss in the 3 months before study entry. (10) 66 (86) 7 (8) 80 (92) 6 (8) 69 (87) Thrombocytopenia c 6 (8) 16 (21) 4 (5) 16 (18) 6 (8) 16 ( (24) 52 (67) 12 (14) 62 (70) 20 (24) 54 (66) Sensory neuropathy 11 (14) 47 (60) 15 (17) 63 (72) 8 (10) (4) 17 (22) 1 (1) 12 (14) 3 (4) 11 (13) Mucositis, clinical exam 1 (1) 5 (6) 4 (5) 21 (24) 1 (1) 14 (17) Hand-foot 2 (3) 7 (9) 2 (2) 10 (11) 6 (7) 21 (26) Nail changes 2 (3) 7 (9) 1 (1) 13 (15) 4 (5) 18 ( of study treatment, the proportion reporting at least one treatment-emergent AE was similar across the three arms (TE 97%; TEF 100%; and TEX 96%). Grade 3/4 AEs were reported in 77%, 61%, and 67% of patients in the TE, TEF, and TEX arms, respectively. The frequency of serious AEs was numerically lower among patients treated with TEF (27% [of which 25% were grade 3/4]) than among those treated with TE (45% [37%]) or TEX (44% [38%] ). The most common haematological (laboratory evaluated) and non-haematological AEs are summarized in Table 2 . Grade 3/4 neutropenia and leukopenia appeared to be slightly more frequent with TE compared with the other two arms. Febrile neutropenia was reported in 8% of patients overall (TE: 14%; TEF: 2%; and TEX: 9%). The most commonly reported non-haematological grade 3/4 AEs across the three arms were fatigue (21%), sensory neuropathy (14%), and diarrhoea (13%).
A total of 18 patients experienced AEs that resulted in death (4 [5%], 3 [3%], and 11 [13%] patients in the TE, TEF, and TEX arms, respectively). The majority of deaths (60%) were attributed to disease progression and were not considered to be drug-related.
The therapeutic index was better with the TEF regimen than with both TEX and TE (Figure 3) . TEF also showed an improved therapeutic index when compared with previously published data for DCF and CF [10] . discussion Although DCF is a standard, effective treatment of advanced or metastatic GC, its use is limited by toxicity. Therefore, it is important to conduct robust, prospective clinical trials to test the tolerability and therapeutic index of potentially less toxic docetaxel/platinum/fluoropyrimidine regimens. In this phase II study, treatment with an optimized TEF regimen was associated with improved PFS, OS, and ORR compared with TE and TEX. A multivariate analysis demonstrated that treatment with TEF (as opposed to either TE or TEX) was a favourable prognostic factor for both PFS and OS. The median OS of >14 months with TEF is substantially better than the 8-9 months' reported in previous international multicentre studies in advanced GC [3] [4] [5] [6] [7] [8] .
In general, the safety profile of TEF was better than that of the other two regimens, although the incidence of neutropenia and leukopenia was high across the three treatment arms. The improved toxicity profile of TEF, including a lower incidence of febrile neutropenia, relative to TE may have been due to the docetaxel dose schedule used (a lower dose every 2 weeks with TEF versus a higher dose every 3 weeks with TE). This study did not demonstrate that oral capecitabine may be an alternative to infusional 5-FU. The reason for the lower efficacy (PFS and OS) observed with the capecitabine triplet compared with the 5-FU triplet is not clear, although patient compliance with capecitabine was relatively poor compared with 5-FU (57% versus 100%). Further combination studies with different capecitabine dosing and schedules may be warranted. Although improved patient survival is usually the primary objective of oncology trials, such improvements may be offset by unacceptable toxicity. For this reason, we evaluated the overall benefit of the regimens investigated in this trial using a therapeutic index relating PFS to a key measure of tolerability, febrile neutropenia. Using this index, TEF was very favourable compared with TE and TEX and also with historical data for DCF and CF, thus providing evidence of an improved benefit : risk profile with TEF compared with the standard treatment in advanced GC.
One possible limitation of this trial was the age of the patient population, which, at a mean of 59 years, is younger than the typical population of patients with GC [23] . This was probably due to the clinical characteristics of the included patients (good performance status and lack of comorbidities). Patient selection is a common limitation in phase II/III trials as demonstrated in previous studies of docetaxel in GC [10, 19, 20] . Nonetheless, the better performance status associated with a younger patient population should be considered when assessing tolerability in this trial. The tolerability of triplet regimens in elderly GC patients is the subject of continued debate [21] . Results of a recent study in elderly patients (≥65 years) with gastro-oesophageal carcinoma suggest that docetaxel-containing triplet regimens are feasible in this age group, although reduced clinical activity and increased toxicity become problematic in patients 70 years of age or older [24] .
In conclusion, the results of this trial provide the rationale for a phase III trial evaluating TEF in advanced GC and, based on the relatively favourable safety profile, TEF at the current dose schedule could act as a chemotherapy platform to combine with other novel biologicals.
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